New opportunities for RGD-engineered metal nanoparticles in cancer

• Published in: Molecular cancer Vol. 22; no. 1; p. 87
• Main Authors: Qin, Wei, Chandra, Jyoti, Abourehab, Mohammed A S, Gupta, Neelima, Chen, Zhe-Sheng, Kesharwani, Prashant, Cao, Hui-Ling
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.05.2023; BioMed Central; BMC
• Subjects: Amino Acid Sequence; Angiogenesis; Aspartate; Blood vessels; Book publishing; Cancer; Cancer imaging; Cancer therapies; Cell adhesion molecules; Clinical outcomes; Contrast agents; Drug targeting; Glycine; Humans; Integrin; Integrins; Ligands; Magnetic resonance imaging; Medical research; Metal Nanoparticles; Nanomaterials; Nanoparticles; Nanotechnology; Neoplasms; Oligopeptides; Optical properties; Peptides; Publishing industry; R&D; Radiation; Research & development; Review; RGD; Silver; Surveillance; Tomography; Toxicity; Tumors; United States; United Kingdom; Metal nanoparticles; Drug targeting; cancer; Integrin; Cancer imaging; RGD
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-023-01784-0

The advent of nanotechnology has opened new possibilities for bioimaging. Metal nanoparticles (such as gold, silver, iron, copper, etc.) hold tremendous potential and offer enormous opportunities for imaging and diagnostics due to their broad optical characteristics, ease of manufacturing technique, and simple surface modification. The arginine-glycine-aspartate (RGD) peptide is a three-amino acid sequence that seems to have a considerably greater ability to adhere to integrin adhesion molecules that exclusively express on tumour cells. RGD peptides act as the efficient tailoring ligand with a variety of benefits including non-toxicity, greater precision, rapid clearance, etc. This review focuses on the possibility of non-invasive cancer imaging using metal nanoparticles with RGD assistance.